Integration Defective Lentiviral Vectors for Transient Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches face challenges in inducing immune tolerance without relying on stable long-term genetic modification of recipient cells, which can lead to safety concerns such as insertional mutagenesis and immune responses against therapeutic proteins.
Innovation Solution
The use of integration defective lentiviral vectors (IDLV) with microRNA (miRNA)-regulated transgene expression, which achieves transient and low-level expression in peripheral organ cells, avoiding hematopoietic lineage cells and thus minimizing integration into the host genome, to induce immunological tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stable long-term genetic modification is used to induce immune tolerance, then immune tolerance is achieved, but safety concerns such as insertional mutagenesis and immune responses against therapeutic proteins arise
Solution Approach 1:
The patent employs transient expression vectors that provide temporary gene expression rather than stable integration. These vectors deliver the transgene for a limited period sufficient to induce immune tolerance, then naturally degrade without permanent genomic modification, thereby avoiding insertional mutagenesis while achieving the desired immunological effect
Solution Approach 2:
The invention extracts the essential function of stable gene expression (inducing immune tolerance) from the problematic stable integration mechanism. By using transient vectors, the patent separates the beneficial immunological outcome from the harmful genomic integration, achieving tolerance induction without permanent genetic modification
2Productivity
If viral vectors are used to deliver transgenes, then gene transfer efficiency is improved, but immune responses against therapeutic proteins increase
Solution Approach 1:
The patent uses vectors with controllable and transient expression dynamics rather than constitutive stable expression. The transgene is expressed at high levels temporarily to establish immune tolerance, then expression naturally declines, creating a dynamic expression profile that induces tolerance while minimizing prolonged immune stimulation
Solution Approach 2:
The invention implements periodic or transient gene expression through temporary vector presence rather than continuous expression. The vector delivers the transgene for a specific period, allowing the immune system to encounter the antigen under controlled temporal conditions that favor tolerance induction over immune activation
3Quantity of substance
If lentiviral vectors with high-level expression are used, then transgene expression is robust, but the risk of insertional mutagenesis and oncogenesis increases
Solution Approach 1:
The patent employs transient expression vectors that provide temporary high-level gene expression rather than stable integration. These vectors deliver the transgene at sufficient levels to induce immune tolerance during a limited period, then naturally degrade without permanent genomic modification, thereby achieving robust transient expression without the oncogenesis risk associated with stable high-level expression
Solution Approach 2:
The invention uses transient vectors as a cushioning approach, providing sufficient transgene expression during the critical window needed for immune tolerance induction, but avoiding permanent integration that would create long-term safety risks. The temporary nature of the vector provides a safety buffer against oncogenesis
Data Source
AI summary
A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells.